A Potential Additional Variable to Consider in the Surgical Treatment of Ductal Carcinoma in Situ.
Conclusion: Based on these results, an HER2-positive ductal carcinoma in situ is likely to be larger than an HER2-negative tumor, leading to more frequent use of mastectomy. This finding would explain our poor recruitment to the National Surgical Adjuvant Breast and Bowel Project Protocol B-43 trial.
PMID: 29230119 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research
More News: Breast Carcinoma | Breast Conservation Surgery | Breast Lumpectomy | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | General Medicine | HER2 | Herceptin | Hormones | Lumpectomy | Mastectomy | Study